FDA Confirms Strattera Safe for Generic ADHD Treatment Production
Published Date: 4/6/2026
Notice
Summary
The FDA confirmed that STRATTERA capsules in all strengths weren’t pulled from the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, helping patients access affordable ADHD treatment without interruption. No changes in price or availability are expected, so everyone can breathe easy!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Generics Eligible for ANDA Approval
The FDA found that STRATTERA (atomoxetine hydrochloride) capsules — 5 mg, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg — were not withdrawn from sale for reasons of safety or effectiveness. Because of this, FDA will not begin procedures to withdraw approval of ANDAs that refer to this product and may continue approving new ANDAs that reference it as long as they meet legal and regulatory requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in